895 related articles for article (PubMed ID: 14594508)
1. Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study.
Babatz J; Röllig C; Oelschlägel U; Zhao S; Ehninger G; Schmitz M; Bornhäuser M
J Hematother Stem Cell Res; 2003 Oct; 12(5):515-23. PubMed ID: 14594508
[TBL] [Abstract][Full Text] [Related]
2. Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy.
Curti A; Isidori A; Ferri E; Terragna C; Neyroz P; Cellini C; Ratta M; Baccarani M; Lemoli RM
Leuk Lymphoma; 2004 Jul; 45(7):1419-28. PubMed ID: 15359643
[TBL] [Abstract][Full Text] [Related]
3. Characterization of canine monocyte-derived dendritic cells with phenotypic and functional differentiation.
Wang YS; Chi KH; Liao KW; Liu CC; Cheng CL; Lin YC; Cheng CH; Chu RM
Can J Vet Res; 2007 Jul; 71(3):165-74. PubMed ID: 17695590
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of dendritic cell generation for clinical use: recovery and purity of monocytes and mature dendritic cells after immunomagnetic sorting or adherence selection of CD14+ starting populations.
Meyer-Wentrup F; Burdach S
J Hematother Stem Cell Res; 2003 Jun; 12(3):289-99. PubMed ID: 12857370
[TBL] [Abstract][Full Text] [Related]
5. Apoptosis of monocytes and the influence on yield of monocyte-derived dendritic cells.
Bohnenkamp HR; Burchell JM; Taylor-Papadimitriou J; Noll T
J Immunol Methods; 2004 Nov; 294(1-2):67-80. PubMed ID: 15604017
[TBL] [Abstract][Full Text] [Related]
6. Generation of CMRF-44+ monocyte-derived dendritic cells: insights into phenotype and function.
Vuckovic S; Fearnley DB; Mannering SI; Dekker J; Whyte LF; Hart DN
Exp Hematol; 1998 Dec; 26(13):1255-64. PubMed ID: 9845382
[TBL] [Abstract][Full Text] [Related]
7. Cryopreservation of monocytes is superior to cryopreservation of immature or semi-mature dendritic cells for dendritic cell-based immunotherapy.
Hayden H; Friedl J; Dettke M; Sachet M; Hassler M; Dubsky P; Bachleitner-Hofmann T; Gnant M; Stift A
J Immunother; 2009; 32(6):638-54. PubMed ID: 19483645
[TBL] [Abstract][Full Text] [Related]
8. Molecular and functional characteristics of dendritic cells generated from highly purified CD14+ peripheral blood monocytes.
Pickl WF; Majdic O; Kohl P; Stöckl J; Riedl E; Scheinecker C; Bello-Fernandez C; Knapp W
J Immunol; 1996 Nov; 157(9):3850-9. PubMed ID: 8892615
[TBL] [Abstract][Full Text] [Related]
9. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
10. Generation of dendritic cells from CD14+ monocytes positively selected by immunomagnetic adsorption for multiple myeloma patients enrolled in a clinical trial of anti-idiotype vaccination.
Motta MR; Castellani S; Rizzi S; Curti A; Gubinelli F; Fogli M; Ferri E; Cellini C; Baccarani M; Lemoli RM
Br J Haematol; 2003 Apr; 121(2):240-50. PubMed ID: 12694245
[TBL] [Abstract][Full Text] [Related]
11. Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha for use in cancer immunotherapy.
Morse MA; Zhou LJ; Tedder TF; Lyerly HK; Smith C
Ann Surg; 1997 Jul; 226(1):6-16. PubMed ID: 9242332
[TBL] [Abstract][Full Text] [Related]
12. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial.
Van Driessche A; Van de Velde AL; Nijs G; Braeckman T; Stein B; De Vries JM; Berneman ZN; Van Tendeloo VF
Cytotherapy; 2009; 11(5):653-68. PubMed ID: 19530029
[TBL] [Abstract][Full Text] [Related]
13. Granulocyte-macrophage colony-stimulating factor drives monocytes to CD14low CD83+ DCSIGN- interleukin-10-producing myeloid cells with differential effects on T-cell subsets.
Ganguly D; Paul K; Bagchi J; Rakshit S; Mandal L; Bandyopadhyay G; Bandyopadhyay S
Immunology; 2007 Aug; 121(4):499-507. PubMed ID: 17433076
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cell-based vaccines in the setting of peripheral blood stem cell transplantation: CD34+ cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells.
Choi D; Perrin M; Hoffmann S; Chang AE; Ratanatharathorn V; Uberti J; McDonagh KT; Mulé JJ
Clin Cancer Res; 1998 Nov; 4(11):2709-16. PubMed ID: 9829733
[TBL] [Abstract][Full Text] [Related]
15. In vitro generation of dendritic cells from human blood monocytes in experimental conditions compatible for in vivo cell therapy.
Cao H; Vergé V; Baron C; Martinache C; Leon A; Scholl S; Gorin NC; Salamero J; Assari S; Bernard J; Lopez M
J Hematother Stem Cell Res; 2000 Apr; 9(2):183-94. PubMed ID: 10813531
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells.
Eyrich M; Schreiber SC; Rachor J; Krauss J; Pauwels F; Hain J; Wölfl M; Lutz MB; de Vleeschouwer S; Schlegel PG; Van Gool SW
Cytotherapy; 2014 Jul; 16(7):946-64. PubMed ID: 24831836
[TBL] [Abstract][Full Text] [Related]
17. Enhanced T-cell activation and T-cell-dependent IL-2 production by CD83+, CD25high, CD43high human monocyte-derived dendritic cells.
Velten FW; Rambow F; Metharom P; Goerdt S
Mol Immunol; 2007 Mar; 44(7):1544-50. PubMed ID: 17023048
[TBL] [Abstract][Full Text] [Related]
18. Efficient presentation of tumor idiotype to autologous T cells by CD83(+) dendritic cells derived from highly purified circulating CD14(+) monocytes in multiple myeloma patients.
Ratta M; Curti A; Fogli M; Pantucci M; Viscomi G; Tazzari P; Fagnoni F; Vescovini R; Sansoni P; Tura S; Lemoli RM
Exp Hematol; 2000 Aug; 28(8):931-40. PubMed ID: 10989194
[TBL] [Abstract][Full Text] [Related]
19. Generation of a dendritic cell-based vaccine in chronic lymphocytic leukaemia using CliniMACS platform for large-scale production.
Adamson L; Palma M; Choudhury A; Eriksson I; Näsman-Glaser B; Hansson M; Hansson L; Kokhaei P; Osterborg A; Mellstedt H
Scand J Immunol; 2009 Jun; 69(6):529-36. PubMed ID: 19439014
[TBL] [Abstract][Full Text] [Related]
20. Clinical-scale generation of dendritic cells in a closed system.
Sorg RV; Ozcan Z; Brefort T; Fischer J; Ackermann R; Müller M; Wernet P
J Immunother; 2003; 26(4):374-83. PubMed ID: 12843800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
